Praxis Bioresearch Seeks Regulatory Strategy Support from MMS Holdings to Develop Therapeutics for Alzheimer’s Disease

MMS Holdings – a data-focused clinical research organization – supported Praxis Bioresearch in the development of a therapeutic for apathy in Alzheimer’s disease. Praxis recently received a $2.9 Million Fast-Track SBIR Grant, which, along with the positive clinical data from the Phase 0 program, means the company’s lead development candidate can now advance to early clinical development.

CluePoints Shortlisted for Multiple Awards in Recognition of Pioneering Risk-Based Quality Management Solution

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has announced it has been shortlisted for three international awards. CluePoints, BioNTech and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) has been selected as a finalist for the Clinical Advance of the Year - COVID-19 Pandemic Special Recognition Award at the Scrip Awards. The company is also in the running for two Citeline Awards: ´Best Sponsor-facing Technology Initiative´ for their business intelligence platform, BEYOND. As well as ´Excellence in Innovation in Response to COVID-19 - Clinical Trial Activities´, for its work with Pfizer / BioNTech.

AVIA Expands Leadership Team to Support Industry Demand for Digital Advancement, Commitment to Operational Excellence

AVIA, the nation’s leading digital transformation partner for healthcare organizations, announced today the expansion of its leadership team to support the substantial growth of the company in 2021

Purdue University and physIQ partner to develop a smartwatch-based algorithm to detect early signs of viral infections, including COVID-19

Purdue University and physIQ, a leader in digital medicine, announced Thursday (Oct. 28) the co-development of a viral detection algorithm for smartwatches. This innovation will be the result of a collaboration between physIQ and university engineers. The algorithm will be commercialized by physIQ, which develops solutions designed to improve health care outcomes by applying artificial intelligence to real-time physiological data from wearable sensors.

Rho to Coordinate NIAID COVID‐19 Vaccine Study in Autoimmune Disease Non‐Responders

Rho , a full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it will be the Statistical and Clinical Coordinating Center for the COVID-19 Vaccine in Autoimmune Disease Non-Responders study. This clinical trial will assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune diseases who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune diseases improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.

CD Formulation Offers Multiple Methods for Microbial Limit Test

LIQUID STABLE & READY-TO-USE TOTAL PROTEIN / ALBUMIN CLINICAL REFERENCE MATERIALS AVAILABLE FROM VERICHEM LABORATORIES

An extensive offering of liquid stable and ready-to-use combined Total Protein/Albumin clinical reference materials are now available from VERICHEM specifically designed and manufactured for the calibration and calibration verification of the analytes on a large number of clinical testing systems,

PreOmics launches BeatBox at ASMS 2021 for high throughput tissue homogenization

Introducing BeatBox: PreOmics launches its new sample preparation tool for tissues and cells

Emmes launches Orphan Reach™: Emmes’ Rare Disease Center

The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs

Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline

The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.

Gundersen Health System Partners with Kyruus to Propel Digital Access Transformation

Innovative Wisconsin-Based Healthcare Network Deploying Kyruus ProviderMatch® Platform to Modernize How Consumers Find Providers Online

2bPrecise Joins the Epic App Orchard to Bring Its Precision Medicine Insights to the Point of Care

2bPrecise™ announced its Precision Health™ platform is now available in the Epic App Orchard Gallery.

Exclusive interview with Professor Sir John Bell announced as Life Science Integrates celebrates ten years of Pharma Integrates

Life Science Integrates (LSI) is delighted to announce the exciting agenda for its flagship event, Pharma Integrates, held live online on 16th November 2021.

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Swiss CDMO Invests in Powder Containment and Extends Spray Drying Capabilities

Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services

Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base

Qlucore approved for listing on Nasdaq First North Growth Market

Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.

CMOs will account for four of the five top bio manufacturing capacities in 2025

230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development

The Community Blood Center (Appleton, WI) to roll out biolog-id’s technology to support platelet lifecycle management

The Community Blood Center is the latest regional blood center to embrace biolog-id’s technology. Biolog-id’s solution for platelet lifecycle management will be deployed to support the efficiency of platelet manufacturing, documentation, and inventory management.

Pillar VC and Petri Announce Winners of $200K Pitch Competition

Pillar VC and Petri have announced the winners of the $200K Pitch Competition that took place during the Founder-Led Biotech Summit, a free virtual event that brought together biotech founders, faculty, PhDs, scientists, investors, and executives to support the founder-led biotech movement.